Clinic Roundup
GenSpera Inc., of San Antonio, said UK regulators cleared the firm for a Phase II trial of G-202 in prostate cancer patients who have failed prior hormonal therapy. The study is expected to enroll up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant disease.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.